Cargando…

Buprenorphine exposure levels to optimize treatment outcomes in opioid use disorder

The severity of the ongoing opioid crisis, recently exacerbated by the COVID-19 pandemic, emphasizes the importance for individuals suffering from opioid use disorder (OUD) to have access to and receive efficacious, evidence-based treatments. Optimal treatment of OUD should aim at blocking the effec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Laffont, Celine M., Ngaimisi, Eliford, Gopalakrishnan, Mathangi, Ivaturi, Vijay, Young, Malcolm, Greenwald, Mark K., Heidbreder, Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715596/ https://www.ncbi.nlm.nih.gov/pubmed/36467036 http://dx.doi.org/10.3389/fphar.2022.1052113

Ejemplares similares

Population Pharmacokinetics of a Monthly Buprenorphine Depot Injection for the Treatment of Opioid Use Disorder: A Combined Analysis of Phase II and Phase III Trials
por: Jones, Aksana K., et al.
Publicado: (2020)

History of the discovery, development, and FDA-approval of buprenorphine medications for the treatment of opioid use disorder
por: Heidbreder, Christian, et al.
Publicado: (2023)

Examining the benefit of a higher maintenance dose of extended-release buprenorphine in opioid-injecting participants treated for opioid use disorder
por: Greenwald, Mark K., et al.
Publicado: (2023)

Evaluation of the Effects of a Monthly Buprenorphine Depot Subcutaneous Injection on QT Interval During Treatment for Opioid Use Disorder
por: Schmith, Virginia D., et al.
Publicado: (2019)

Population pharmacokinetics of buprenorphine and naloxone sublingual combination in Chinese healthy volunteers and patients with opioid use disorder: Model-based dose optimization
por: Gu, Meng, et al.
Publicado: (2023)

A Delta-Opioid Receptor Gene Polymorphism Moderates the Therapeutic Response to Extended-Release Buprenorphine in Opioid Use Disorder
por: Kranzler, Henry R, et al.
Publicado: (2020)

Pharmacokinetics of Sublingual Buprenorphine Tablets Following Single and Multiple Doses in Chinese Participants With and Without Opioid Use Disorder
por: Dong, Ruihua, et al.
Publicado: (2019)

Treatment of opioid dependence with buprenorphine: current update
por: Soyka, Michael
Publicado: (2017)

Transition From Full Mu Opioid Agonists to Buprenorphine in Opioid Dependent Patients—A Critical Review
por: Soyka, Michael
Publicado: (2021)

Impact of Population and Pharmacogenetics Variations on Efavirenz Pharmacokinetics and Immunologic Outcomes During Anti-Tuberculosis Co-Therapy: A Parallel Prospective Cohort Study in Two Sub-Sahara African Populations
por: Mugusi, Sabina, et al.
Publicado: (2020)

Treating Opioid Use Disorder With a Monthly Subcutaneous Buprenorphine Depot Injection: 12-Month Safety, Tolerability, and Efficacy Analysis
por: Andorn, Anne C., et al.
Publicado: (2020)

Optimal single sampling time-point for monitoring of praziquantel exposure in children
por: Mnkugwe, Rajabu Hussein, et al.
Publicado: (2021)

Buprenorphine‐naloxone, buprenorphine, and methadone throughout pregnancy in maternal opioid use disorder
por: Kanervo, Minna M., et al.
Publicado: (2022)

Managing opioid withdrawal precipitated by buprenorphine with buprenorphine
por: Oakley, Bridget, et al.
Publicado: (2021)

Prescription amphetamines in people with opioid use disorder and co-occurring psychostimulant use disorder initiating buprenorphine: an analysis of treatment retention and overdose risk
por: Tardelli, Vitor, et al.
Publicado: (2023)

The Pharmacology of Buprenorphine Microinduction for Opioid Use Disorder
por: De Aquino, Joao P., et al.
Publicado: (2021)

Recovery From Opioid Use Disorder (OUD) After Monthly Long-acting Buprenorphine Treatment: 12-Month Longitudinal Outcomes From RECOVER, an Observational Study
por: Ling, Walter, et al.
Publicado: (2020)

Deuterated buprenorphine retains pharmacodynamic properties of buprenorphine and resists metabolism to the active metabolite norbuprenorphine in rats
por: Janganati, Venumadhav, et al.
Publicado: (2023)

Methadone, Buprenorphine, and Clonidine Attenuate Mitragynine Withdrawal in Rats
por: Hassan, Rahimah, et al.
Publicado: (2021)

Evaluation of Drug‐Drug Interaction Liability for Buprenorphine Extended‐Release Monthly Injection Administered by Subcutaneous Route
por: Kharidia, Jahnavi, et al.
Publicado: (2021)

Personalized Care in Opioid Use Disorder maintained on Buprenorphine
por: Elarabi, H., et al.
Publicado: (2022)

Inpatient Buprenorphine Induction for Opioid Use Disorder in Pregnancy
por: Tavakoli, Amin, et al.
Publicado: (2023)

Patients Maintained on Buprenorphine for Opioid Use Disorder Should Continue Buprenorphine Through the Perioperative Period
por: Lembke, Anna, et al.
Publicado: (2019)

Pharmacometric dose optimization of buprenorphine in neonatal opioid withdrawal syndrome
por: Eudy‐Byrne, Rena, et al.
Publicado: (2021)

Editorial: Opioids and opioid-use disorders
por: de Guglielmo, Giordano, et al.
Publicado: (2023)

The introduction of a novel formulation of buprenorphine into organized health systems()()
por: Mullen, William, et al.
Publicado: (2022)

Comparison of Buprenorphine and Buprenorphine/naloxone in Detoxification of Opioid-dependent Men
por: Ziaaddini, Hassan, et al.
Publicado: (2018)

Buprenorphine Dosage and Urine Quantitative Buprenorphine, Norbuprenorphine, and Creatinine Levels in an Office-Based Opioid Treatment Program
por: Furo, Hiroko, et al.
Publicado: (2021)

A review of the pharmacogenomics of buprenorphine for the treatment of opioid use disorder
por: Seguí, Hemanuel Arroyo, et al.
Publicado: (2020)

Hospitalist perspectives on buprenorphine treatment for inpatients with opioid use disorder
por: Reed, Megan K, et al.
Publicado: (2022)

Pharmacy Availability of Buprenorphine for Opioid Use Disorder Treatment in the US
por: Weiner, Scott G., et al.
Publicado: (2023)

Corrigendum to: Pharmacometric dose optimization of buprenorphine in neonatal opioid withdrawal syndrome
Publicado: (2022)

Prescribing of Opioid Analgesics and Buprenorphine for Opioid Use Disorder During the COVID-19 Pandemic
por: Currie, Janet M., et al.
Publicado: (2021)

Advances in the delivery of buprenorphine for opioid dependence
por: Rosenthal, Richard N, et al.
Publicado: (2017)

Role of Buprenorphine in an Adolescent with Opioid Abuse
por: Weesner, Elizabeth, et al.
Publicado: (2022)

Mobile Telemedicine for Buprenorphine Treatment in Rural Populations With Opioid Use Disorder
por: Weintraub, Eric, et al.
Publicado: (2021)

Economic Evaluation of Extended-Release Buprenorphine for Persons With Opioid Use Disorder
por: Flam-Ross, Juliet M., et al.
Publicado: (2023)

A buprenorphine-validated rat model of opioid use disorder optimized to study sex differences in vulnerability to relapse
por: Bakhti-Suroosh, Anousheh, et al.
Publicado: (2021)

Modeling buprenorphine reduction of fentanyl-induced respiratory depression
por: Olofsen, Erik, et al.
Publicado: (2022)

Buprenorphine for Medication-Assisted Treatment of Opioid Use Disorder in Pregnancy: Relationship to Neonatal Opioid Withdrawal Syndrome
por: Chavan, Niraj R., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_jamm3ho52adk1nm8bg8jtbf4kt